Clinical Trial

Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Clinical Study on the Safety and Efficacy of the efficacy and safety of Adebrelimab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-11; most recent amendment 2025-11-14.
Status change: Recruiting → Not Yet Recruiting 2025-11-14
Trial Details
NCT Number NCT06177522
Lead Sponsor Jinling Hospital, China
Collaborators: Jiangsu Hengrui Pharmaceutical Co., Ltd.
Conditions Pancreatic Cancer, Neoadjuvant Therapy
Enrollment 30 participants
Start Date 2025-11-30
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-18